Eleven currently available clinical guidelines for ANCA-associated vasculitis (AAV) were appraised using the AGREE II instrument (23 criteria across 6 domains) by 4 independent reviewers to identify gaps and suggest improvements.
The average AGREE II score across all 11 guidelines was 4.5 ± 0.8 out of 7.0; the British Society for Rheumatology 2025 guideline scored highest (5.8/7.0) and was the only one unanimously recommended for use. The weakest domain was Applicability (D5), with poor scores for implementation tools, resource/cost implications, and audit criteria; patient involvement (D2) was also consistently lacking.
Only 4 reviewers appraised the guidelines, which limits the breadth of perspective; the AGREE II tool evaluates guideline quality and reporting rather than clinical content accuracy or outcomes; and the appraisal reflects guidelines available at a single point in time.
Clinicians managing AAV should preferentially consult the BSR 2025 guidelines, which currently meet the highest methodological standards. Guideline developers should prioritize incorporating patient perspectives and practical implementation tools in future AAV guideline updates.
Explore related topics